Clinical trial Recruiting at 17 sites Interventional Ages 18 to 80

Comparing radiofrequency ablation and Doppler-guided ligation for treating hemorrhoids

Official title: Radiofrequency Haemorrhoidal Thermoablation Versus Doppler-guided Haemorrhoidal Artery Ligation With Mucopexy in the Treatment of Haemorrhoidal Disease: a Multicenter Randomized Non-inferiority Trial

Run by Centre Hospitalier Departemental Vendee · NCT06170736 · Data updated 2026-11-12

This study is testing whether a new method called radiofrequency ablation works as well as another method called Doppler-guided ligation for treating bothersome internal hemorrhoids.

Quick facts

Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment168 (estimated)
SponsorCentre Hospitalier Departemental Vendee
Academic / other
Locations18 sites (Amiens and 17 other locations)
StatusRecruiting
StartedFebruary 21, 2024
Main results expectedFebruary 15, 2028
Study endsSeptember 15, 2030
Registry record updatedMarch 13, 2026
Trial IDNCT06170736 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults with symptomatic Grade II or III hemorrhoids requiring surgical management.

Probably not a fit

Patients with hemostasis disorders, external hemorrhoidal disease, or a history of colorectal cancer may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to compare the effectiveness of radiofrequency ablation (RFA) and Doppler-guided haemorrhoidal artery ligation (DGHAL) in treating symptomatic Grade II and III internal hemorrhoids. Both procedures are minimally invasive alternatives to traditional hemorrhoidectomy, with RFA showing promising outcomes and lower recurrence rates in preliminary studies. The trial will assess the non-inferiority of RFA compared to DGHAL in terms of failure rates, providing valuable insights into the best treatment options for patients. Participants will be monitored for postoperative outcomes to determine the most effective approach.

Why it matters

Potential benefit: If successful, this study could provide patients with a more effective and less recurrent treatment option for hemorrhoidal disease.

How similar studies have gone: While there have been successful studies on RFA for hemorrhoids, this is the first to directly compare it with DGHAL.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Major patient,
* With symptomatic Grade II or III haemorrhoidal disease,
* Requiring surgical management,
* Patient able to understand the protocol and having given written informed consent to participate in the study,
* Patient affiliated to the social security system or entitled to it.

Exclusion Criteria:

* Hemostasis disorders
* Active external haemorrhoidal disease (thrombosis)
* History of surgical procedure for treatment of haemorrhoids (instrumental treatment is not a contra-indication)
* Associated proctological pathology (anal fissure, chronic suppuration, external rectal prolapse)
* History of colorectal cancer
* History of inflammatory bowel disease
* History of rectal resection
* Patient participating in another interventional clinical research protocol involving a drug or clinical investigation of a medical device
* Patient who is pregnant, breastfeeding or able to procreate without effective contraception\* at the time of inclusion
* Patient under guardianship, curators or deprived of liberty.
* Patient under court protection.

  * oral contraceptive (pill), monthly vaginal ring, weekly transdermal patch, subcutaneous implant, intrauterine devices (IUD), or sterilisation.

Where it's running

  • Centre Hospitalier Universitaire
    Amiens, France
    Recruiting
  • Centre Hospitalier Universitaire
    Angers, France
    Recruiting
  • Maison de Santé Bagatelle
    Bordeaux, France
    Recruiting
  • Centre Hospitalier Privé
    Brest, France
    Recruiting
  • Clinique du val d'Ouest
    Écully, France
    Recruiting
  • Centre Hospitalier Départemental de Vendée
    La Roche-sur-Yon, France
    Recruiting
Show 12 more locations
  • Hôpital de la Louvière
    Lille, France
    Recruiting
  • CHU Limoges
    Limoges, France
    Recruiting
  • Clinique de la Sauvegarde
    Lyon, France
    Recruiting
  • Centre Hospitalier Universitaire
    Nantes, France
    Recruiting
  • Clinique Jules Verne
    Nantes, France
    Recruiting
  • Hôpital Saint Joseph
    Paris, France
    Recruiting
  • Institut Mutualiste Montsouris
    Paris, France
    Recruiting
  • Centre Hospitalier Interrégional
    Poissy, France
    Recruiting
  • Centre Hospitalier Universitaire
    Rennes, France
    Recruiting
  • hôpital d'Instruction des Armées
    Saint-Mandé, France
    Recruiting
  • Clinique de l'Estuaire
    Saint-Nazaire, France
    Recruiting
  • Cabinet de Proctologie
    Saint-Herblain, France
    Not yet recruiting

Study contacts

  • Principal investigator: Marc-Henri JEAN, Dr — Centre Hospitalier Departemental Vendée
  • Study coordinator: Agnès DORION
  • Email: agnes.dorion@ght85.fr
  • Phone: 251446380

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.